The effect of green tea extract supplementation on sputum smear conversion and weight changes in pulmonary TB patients: A randomized controlled trial

Mohammad Reza Honarvar¹, Shahyar Eghtesadi*², Pooria Gill³, Shima Jazayeri⁴
Mohammad Ali Vakili⁵, Mohammad Reza Shamsardekani⁶, Abdollah Abbasi⁷

Received: 20 August 2015 Accepted: 21 February 2016 Published: 1 June 2016

Abstract
Background: Acceleration in sputum smear conversion helps faster improvement and decreased probability of the transfer of TB. In this study, we aimed to investigate the effect of green tea extract supplementation on sputum smear conversion and weight changes in smear positive pulmonary TB patients in Iran.

Methods: In this double blind clinical study, TB patients were divided into intervention, (n=43) receiving 500 mg green tea extract (GTE), and control groups (n=40) receiving placebo for two months, using balanced randomization. Random allocation and allocation concealment were observed. Height and weight were measured at the beginning, and two and six months post-treatment. Evaluations were performed on three slides, using the ZiehlNeelsen method. Independent and paired t test, McNemar’s, Wilcoxon, Kaplan-Meier, Cox regression model and Log-Rank test were utilized. Statistical significance was set at p<0.05. This trial was registered under IRCT201212232602N11.

Results: The interventional changes and the interactive effect of intervention on weight were not significant (p>0.05). In terms of shortening the duration of conversion, the case to control proportion showed a significant difference (p=0.032). Based on the Cox regression model, the hazard ratio of the relative risk of delay in sputum smear conversion was 3.7 (p=0.002) in the higher microbial load group compared to the placebo group and 0.54 (95% CI: 0.31-0.94) in the intervention compared to the placebo group.

Conclusion: GTE decreases the risk of delay in sputum smear conversion, but has no effect on weight gain. Moreover, it may be used as an adjuvant therapy for faster rehabilitation for pulmonary TB patients.

Keywords: Body Weight, Dietary Supplements, Humans, Sputum, Tea, Tuberculosis, Pulmonary.


Introduction
The Golestan Province of Iran has a high rank of the incidence and prevalence of tuberculosis (1). The patients often suffer from weight loss and malnutrition, mainly due to the high level of oxidative stress because of the disease and decreased food intake. Numerous investigations have been conducted on the effect of nutrition or supplementation of the improvement course of TB (2–5). Supplementation with macro or micronutrients (like vitamin D or arginine) is effective during anti-bacterial therapy and results in the improvement of

¹. PhD Candidate, Department of Nutrition, School of Public Health, Iran University of Medical Sciences, Tehran, Iran. honarvar@goums.ac.ir
². (Corresponding author) Professor, Department of Nutrition, School of Public Health, Iran University of Medical Sciences, Tehran, Iran. seghtesadi@gmail.com
³. Assistant Professor, Departments of PhysioPharmacology & NanoBioMedicine, Research Center for Immunogenetics, Faculty of Medicine, Mazandaran University of Medical Sciences, Sari, Iran. pooriagill@yahoo.com
⁴. Associate Professor, Research Center for Prevention of Cardiovascular Disease, Department of Nutrition, School of Public Health, Iran University of Medical Sciences, Tehran, Iran. sh_jaz@yahoo.com.
⁵. Associate Professor, Research Center for Prevention of Cardiovascular Disease, Department of Nutrition, School of Public Health, Iran University of Medical Sciences, Tehran, Iran. vakili@ouoms.ac.ir
⁶. Professor, Department of Pharmacognosy, Faculty of Pharmacy and Medicinal Plants Research Center, Tehran University of Medical Sciences, Tehran, Iran. ardekani@sina.tums.ac.ir.
⁷. Assistant Professor, Department of Infection, Faculty of Medicine, Golestan University of Medical Sciences, Gorgan, Iran. abdolbas@yahoo.com
the general conditions of the patients and accelerates recovery from TB according to different studies (6–11). Nutraceuticals, like green tea polyphenols, have shown acceptable properties as adjuvant treatment of different diseases. Because of its active polyphenol compounds, Green tea (GT) has a scavenging effect on free radicals and exhibits anti-oxidant properties (12,13). Polyphenols fight inflammation through inhibition of the synthesis and function of inflammatory mediators like eicosanoids and cytokines (14). The increase in the level of inflammatory cytokines of the plasma may be associated with malnutrition in active pulmonary TB (15). Oxidative stress may suppress the immune system. In patients with TB, consumption of antioxidant supplements may tackle oxidative stress. Green tea can protect the immune system against oxidant compounds and free radicals through controlling oxidative stress and boost its function as well (16,17). Green tea may help to accelerate the process of recovery and weight gain in TB patients through decreasing oxidative stress.

Conversion of the sputum smear is an important indicator of treatment after two months of intensive antibiotic therapy in sputum smear positive patients (18). Acceleration in sputum smear conversion helps faster improvement and decreased probability of the transfer of TB in smear-positive patients with tuberculosis. Green tea catechin is an important potential immunotherapeutic agent against respiratory infections and negatively affects the survival of *M. tuberculosis* through inhibition of the NF-κB pathway in vitro (13,19). Therefore, consumption of green tea or supplementation with concentrated polyphenols derived from green tea can be regarded as an adjuvant therapy in patients receiving antibiotics (13).

Considering the lack of such studies in Iran, we aimed to perform this study to evaluate the effect of green tea as an adjuvant therapy on shortening the sputum smear conversion time and weight in patients with smear positive pulmonary tuberculosis. The primary outcome of this study was the sputum smear conversion time and the secondary outcome was changes in weight and BMI within the two months.

**Methods**

**Data and Design**

This double blind clinical trial, with a randomized design, included patients with smear positive pulmonary TB, who were diagnosed with TB based on clinical manifestations and sputum smear positivity according to the guidelines of the Iranian Ministry of Health. The patients received Isoniazid, Rifampin, Pyrazinamide, and Ethambutol according to the DOTS (Directly Observed Treatment, Short course) strategy. All participants were selected from governmental health centers of Golestan Province in Iran. This study was conducted from September 2012 to December 2013.

Inclusion criteria were as follows: Definite diagnosis of the disease according to the guidelines of the Ministry of Health (a positive sputum smear along with clinical and radiologic manifestations); living in the Province of Golestan; receiving treatment in a DOTS program, age 15 years and older; willingness to participate in the study; Non drug-resistant TB; BMI more than 14, and 7); no history of diseases affecting the course of TB including autoimmune diseases like SLE and RA, type 1 diabetes mellitus, thalassemia, hemochromatosis, pregnancy, lactation, and renal failure. The exclusion criteria were as follows: Development of the signs and symptoms of sensitivity to green tea or the complications of its use; severe changes in the liver function tests following the administration of anti TB drugs; and development of severe complications of anti TB medicines.

To achieve an adequate number of patients in the two study groups, we divided the patients who met the inclusion criteria into the two arms of treatment and...
placebo, using block randomization (block size = 2, treatment to placebo proportion= 1:1).

The sample size was calculated to be 40 persons according to a study by Nursyam (20) based on the estimation of 100% sputum conversion in the intervention group and 67.6% in the placebo group, level of significance (α=0.05), test power 90%, and 10% attrition of the samples. With respect to allocation concealment, every new patient was allocated to either group A or B introduced by the health centers of the cities of the province. The name of the groups was placed in a closed envelop with a non-see through covering. For blinding, similar boxes were provided for the green tea or placebo capsules, and the packages were coded as A or B. The boxes containing the capsules were similar with no nametags. An expert who was not involved in the treatment process or supervision delivered the drugs to the DOTS staff based on the designated codes. The treatment staff and patients were unaware of the allocated treatment.

Green tea capsules were purchased from Vitacost Company, USA, with the following specifications:
Green Tea Extract 500mg (Camellia Sinensis) standardized to 98% polyphenols, 80% catechins, 50% EGCG (leaves).

The placebo capsules containing green tea powder without catechin were provided from a local pharmaceutical company.

The dose of 500 mg catechin was selected based on the studies conducted on the effect of green tea on infections, particularly tuberculosis (21).

The intervention group received green tea supplementation and the control group received supplementation with placebo for two months. Both groups received anti TB therapy according to the DOTS protocol under the supervision of a coordinating physician. In this protocol, the patients take their anti TB drugs daily under the direct supervision of a health worker during an intensive phase. The patients receive a 4-drug regimen at the first 2 months, with a two-drug regimen in the following four months of the treatment. Sputum smear evaluation was performed at two and six months post-treatment to assess improvement.

The weight and height of the patients were measured at the beginning of the treatment and after two and six months. Weight was measured, using a Seca Scale (Seka, Hamburg, Germany) with a precision of 0.1kg; and height was measured, using a stadiometer to the nearest of 0.1cm. Body Mass Index (BMI) was calculated using the following formula: Weight (kg)/height(kg)^2. Physical examinations were performed to evaluate the improvement course and weight at 0, 2, and 6 months. From day 20 onward, sputum smears were obtained from the patients every 10 days until they turned negative and sent to the laboratory for evaluation of the microbial load. Trained assistants performed direct smear evaluations on three slides, using the ZiehlNeelsen method, and sputum smear conversion was defined as two negative slides for M. tuberculosis. All the slides were sent to the Central Laboratory of Golestan province for controlling purposes.

Overall, 17 patients were excluded from the analyses according to the exclusion criteria (eight patients were lost to follow-up, nine had illegible data, and three migrated).

**Statistical Analysis**

The results were presented as mean ± SD, median and range (Table 3). Comparison between the two groups was performed using χ^2 and t-test. Repeated measures of ANOVA accounting for three time measurement of weight, group (Green Tea and Placebo) and interaction of time and group were used to assess the differences between the three times for each group and compare the differences between the two groups. Box's test was used for equality of
covariance matrices, Mauchly's test was conducted for sphericity, and Bonferuni as a post hoc test to determine the changes in the three stages. The normality assumption for variables was tested by both the Kolmogorov–Smirnov test and Shapiro-Wilk test. Considering the two-month follow-up, the Kaplan-Meier test was used to calculate the duration of treatment, Cox regression model was utilized to assess the effect of smear rank on survival adjusted for treatment of other prognostic variables, and Log-Rank test was employed to compare the duration of treatment between the two groups. Data were analyzed using SPSS16. To assess the assumption of the appropriateness of risks, a cumulative logarithmic graph was used for all the independent variables in the model, and the results indicated observance of the assumption of appropriateness of risk over time.

Survival time (in months) was calculated from the date of diagnosis to the date of death or last follow-up. Failure was defined as death by any cause during the follow-up period; and the sputum smear conversion time of more than two months was censored in the patients.

The duration of intervention was considered from the commencement of the therapy to the date of sputum conversion in the second month of the treatment. For simpler calculation, we merged the scanty and +1 groups.

**Results**

Forty-one patients (51%) in the green tea group and 39 patients (49%) in the placebo group completed the study (Fig. 1). To explore the relationship between ethnic groups, intervention type and use of chi-square test, data of ethnic groups were considered in three subgroups including Sistani, Turkmen and other (Fars and Afghan). Moreover, to investigate marital status, widowed and divorced were merged; in brief, to conduct the chi-square

---

**Fig. 1. Flow Diagram of the Study Screening and Selection Process**

Assessed for Eligibility \(n=93^*\)

- 10 excluded (5 did not meet inclusion criteria, 2 refused to participate, 3 for other reasons)

83 patients Randomised

- Catechin group 43
  - Lost to follow up 1 Death 1
  - Included in Analysis 39 Excluded from Analysis 2

- Placebo group 40
  - Lost to follow up 0 Death 1
  - Included in Analysis 36 Excluded from Analysis 3

---

http://mjiri.iums.ac.ir
test, high school diploma and academic education were integrated. No significant difference was found between the two groups in the distribution of age, sex and clinical status at the beginning of the treatment (Table 1). In the placebo group, the mean±SD weight of the patients was 53.4±10.4kg at the beginning of the treatment, 54.2±9.97kg at the end of the second month, and 56.1±11.26kg at the end of the sixth month. On average, the patients gained 0.9±1.95kg at the end of the second month and 2.6±2.52 kg at the end of the sixth month (t=4.46, p<0.001). Weight gain at the end of the second and sixth months was significant in both groups.

The results of ANOVA repeated measure revealed that weight gain was different in the control and intervention groups by the time trend, while it was not significantly different between the two groups after two and six months (Table 2).

Sputum samples of 36 patients in the placebo group and 39 patients in the GT group were examined at the beginning and during the treatment (Table 3). The sputum samples of four patients in the GT group and four in the placebo group were excluded from the analysis due to the laboratory or delivery with a delay of more than 30 days. The conversion time was more than 60 days in 16 patients in the placebo and in 12 patients in the GT group;

<table>
<thead>
<tr>
<th>Source</th>
<th>Type III sum of squares</th>
<th>df</th>
<th>Mean square</th>
<th>F</th>
<th>p</th>
</tr>
</thead>
<tbody>
<tr>
<td>Time</td>
<td>302.49</td>
<td>1.67</td>
<td>181.3</td>
<td>62.63</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Group</td>
<td>318.15</td>
<td>1</td>
<td>318.15</td>
<td>0.82</td>
<td>0.37</td>
</tr>
<tr>
<td>Time*Group</td>
<td>1.73</td>
<td>1.67</td>
<td>1.04</td>
<td>0.36</td>
<td>0.66</td>
</tr>
</tbody>
</table>
Table 3. Sputum Smear and Conversion Time of Patients with Pulmonary Tuberculosis from Beginning of the Treatment

<table>
<thead>
<tr>
<th>Sputum smear grade</th>
<th>intervention group (n=39)</th>
<th>Placebo group (n=36)</th>
<th>p</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>N (%)</td>
<td>Mean±SD</td>
<td>N (%)</td>
</tr>
<tr>
<td>Scanty&amp; 1+</td>
<td>19 (52.8%)</td>
<td>32.9±16.42</td>
<td>19 (48.7%)</td>
</tr>
<tr>
<td>2+</td>
<td>8 (20.5%)</td>
<td>37.4±24.13</td>
<td>9 (25%)</td>
</tr>
<tr>
<td>3+</td>
<td>12 (30.8%)</td>
<td>62.1±22.82</td>
<td>8 (22.2%)</td>
</tr>
</tbody>
</table>

*Not significant

and therefore, they were removed from analysis. The mean±SD sputum conversion time (days) was 52.5±24.5 days (median: 53 days) in the placebo group and 40.6±22.5 days (median: 29 days) in the GT group. As demonstrated in Figure 2, the proportion of the patients in the GT group to patients in the placebo group was significantly high in terms of sputum conversion time (Log Rank (Mantel-cox)=4.61 (p=0.032)).

Considering the status of the sputum microbial load, the time of sputum smear conversion was expected to be shorter in the scanty and +1 group versus the +3 group. The two groups of GT and placebo were compared to sputum smear conversion for days considering the
microbial load of the sputum in the beginning of the study. It was found that the sputum smear conversion time was significantly shorter in the GT group than the placebo group (p=0.031) (Fig. 3).

Based on the Cox regression model for considering the simultaneous effect of the microbial load and type of treatment, the hazard ratio of the risk of delay in smear conversion was 3.7 (95% CI: 1.7-8.6, p=0.002) in group 2 vs. group 1; 3.2 (CI 1.2-8.2, p=0.016) in group 3 vs. group 1; and 0.54 (95% CI: 0.31-0.94, p=0.031) in the GT group vs. the placebo group. Therefore, the risk of delay in sputum conversion augmented with the increase in the microbial load and decreased with the consumption of green tea.

Discussion
Our study well documented the effect of catechin on sputum smear conversion. The microbial load of the sputum decreased faster in patients who received catechin compared to the control group.

Range and et al. found no significant difference in the culture conversion rate between patients who received micronutrient supplements and those who received placebo (89.5% versus 86.2%, p=0.29) and reported that zinc had no effect on the culture conversion rate (10). A study by Martins et al. on sputum smear positive TB patients revealed that the proportion of the sputum smear clearance one month after the start of treatment was higher but non-significant in patients receiving food package (85%, n=40) compared to the control group (67%, n=37) (22). In the study by Karyadi, supplements resulted in faster clearance of the sputum smears (15). Nursyam presented that Vit D3 supplementation significantly increased the sputum smear conversion at the end of the sixth week compared to the control group (% 100 compared to % 76.7) (20).

Jahnnavi reported a higher sputum conversion rate (p=0.039) in patients receiving supplements (9). Coussens and et al. found that supplementation with vitamin D accelerated sputum smear conversion. They attributed this finding to the role of vitamin D in decreasing inflammatory responses during TB treatment (23). However, in Martineau et al. study, vitamin D supplementation as 2.5mg did not significantly reduce time to sputum culture conversion in the intervention group compared to the control group (24). In a study by Visser and et al. no significant difference was found in the smear or culture conversion time between the recipients of vitamin A and zinc, using the Kaplan-Meier method (p=0.15 and p=0.38, respectively, log-rank test) (11).

Researchers believed that many factors affect sputum smear conversion. Jayakody and et al. reported that a high grade of smear positivity was associated with failure in sputum smear conversion, whose beliefs were due to the higher initial bacterial load that required a longer time for clearance in the early stages of treatment (25).

Lawson et al. study showed that using Zinc and Retinol as supplementation in patients with pulmonary tuberculosis did not result in improved outcome of disease compared to the placebo. They believed that sputum smear grade is one of the most effective factors on time of sputum conversion (26). Ponnuraja showed that patients with cavitary disease, high sputum smear grade before treatment, or a past history of TB were more likely to experience a delay in sputum smear conversion (p<0.05) (27). In our study, a higher microbial load was correlated with a delay in sputum smear conversion.

The patients in our study were generally underweight at the beginning of the study (39%), but gained weight significantly two months after the commencement of the therapy. Schwenk and et al. noted a weight gain of 8.9%±9.5% in 40 TB patients following six months of standard anti TB treatment in England (28). HOW, S.H reported that 14.7% of patients with pulmonary tuberculosis were yet positive smear after one month (18). Krapp, F and et al. reported an increase in median weight
gain in TB patients at the end of the first month as 2.6 kg, at the end of initial phase as 4.8 kg, and at the end of treatment as 8.2 kg in cured patients (29).

Pharmacotherapy with anti-tuberculosis drugs results in nutrition improvement and weight gain. We reckoned that supplementation with green tea accelerated weight gain in patients since the combination of TB pharmacotherapy and anti-inflammatory compounds accelerate recovery from TB (30), but the results of our intervention indicated a slight increase in weight gain.

Different studies have evaluated different compounds as adjuvant therapy to anti TB treatment. Some of these compounds have shown positive effects on weight gain, while some did not have any effects compared to the control group. A study by Range in Tanzania on multi-micronutrient therapy and zinc supplementation in 530 pulmonary TB patients showed that patients who received supplementation with multi-micronutrients and zinc, weighed 2.4 kg more on average. The mean of total weight gain was 6.88 kg in that study (95% CI 0.1-0.8; RR 0.29) (10). Schön T and et al. in a study conducted on 180 Ethiopian patients with tuberculosis found that food enrichment with arginine had no effect on weight gain in the intervention group compared to the control group (3). In a study implemented by Ralph AP and et al. adjunctive Therapy with L-arginine (six grams daily for 8 weeks) and vitamin D (50,000 IU daily for 4 weeks) for 200 patients with tuberculosis had no effects on weight gain in the intervention group compared to the control group (31).

Previous studies found no difference in weight gain between their intervention and control groups, and this could be due to the sample size or the effect of other factors such as nutrition. These studies mostly used a nutrient (macronutrient or micronutrient), while we used the nutraceutical supplement of green tea. It seems that the contribution of green tea to decrease the inflammatory status of the patients has a little effect on improving the nutritional status of the patients compared to the effect of antibacterial therapy.

Other studies evaluated the status of the inflammatory indices. For example, Kim et al. reported that the levels of TNF-α and IL-6 were higher in malnourished TB patients than the control group and well-nourished TB patients (31). Furthermore, they found that the level of C-reactive protein (CRP) and the proportion of CRP to albumin was lower in patients not afflicted with TB than TB patients 30 and 60 days after treatment (32).

Numerous studies have highlighted the role of green tea, particularly its catechins in regulating inflammatory reactions (13,33-35). Green tea entraps reactive oxygen species (ROS) and is protective against oxidative stress. Agarwal and et al. showed the effect of green tea extract on the reduction of oxidative stress in patients receiving anti TB treatment (21).

To our knowledge, our study was the first to be conducted on the use of green tea extract as a supplement in the treatment of tuberculosis in Iran. The main limitation of our study was the lack of sputum culture, which is considered the gold standard of TB diagnosis. In addition, difficulty obtaining sputum specimens during treatment, due to the clearance of the patients’ lungs, was another limitation of this study. Finally, considering the DOTS protocol, few patients were asked to take a chest X-ray to follow the improvement.

Conclusion
In this study, green tea had a little effect on weight gain; however, its catechins contents are natural compounds with relatively safe profiles, and the use of green tea as an adjuvant therapy in TB patients may be a new method for faster rehabilitation of these patients through shortening the time to sputum smear conversion.

Acknowledgments
The authors wish to thank the staff of the...
Health Centers of Golestan province, research and health authorities of Golestan University of Medical Sciences and Iran University of Medical Sciences for their financial support and the managers of Giah Esans Industry & Agriculture Company for providing the placebo.

**Trial Registration**
This trial was registered under IRCT 201212232602N11.

**References**